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Abstract
Background: Sexually transmitted infection with high-risk, oncogenic strains of human papillomavirus (HPV) still
induces a relevant burden of diseases on both men and women. Although vaccines appear to be highly efficacious in
preventing the infection of the most common high-risk strains (HPV 6, 11, 16, 18), important questions regarding the
appropriate target population for prophylactic vaccination are still debated. Models in the extant literature seem to
converge on the cost-effectiveness of high coverage (>80%) of a single cohort of 12-year-old girls. This vaccination
strategy should provide an adequate level of indirect protection (herd immunity) to the unvaccinated boys. This
argument presupposes the ecological validity of the cost-effectiveness models; the implicit condition that the
characteristics of the individuals and the sexual behaviours observed in the models is generalisable to the natural
behaviours of the population.
The primary aim of this review is to test the ecological validity of the cost-effectiveness models of universal HPV
vaccination available in the literature. The ecological validity of each model will be defined by the number of
representative characteristics and behaviours taken into consideration.
Methods: Nine bibliographic databases will be searched: MEDLINE (via PubMed); Scopus; Science Direct; EMBASE via
OVID SP, Web of Science, DARE, NHIR EED and HTA (via NHIR CRD); and CINHAL Plus. An additional search for grey
literature will be conducted on Google Scholar and Open Grey. A search strategy will be developed for each of the
databases. Data will be extracted following a pre-determined spreadsheet and then clustered and prioritised: the main
outcomes will report the inputs to the demographic and epidemiological model, while additional outcomes will refer
to basic inputs to the cost-effectiveness valuation.
Each study included in the review will be scored by the number of representative characteristics and behaviours taken
into consideration (yes or no) on both dimensions. Individual study’s scores will be plotted in a 2 by 2 matrix: studies
included in the upper right quadrant will be defined as ecologically valid, since which both individuals’ characteristics
and their sexual behaviours are representative.
Discussion: The proposed systematic review will be the first to assess the ecological validity of cost-effectiveness
studies. In the context of sexually transmitted diseases, when this condition is violated, an error in predicting the
protective impact of herd immunity would occur. Hence, a vaccination policy informed on ecologically invalid models
would potentially expose boys to a residual risk of contracting HPV-induced malignancies.
Systematic review registration: PROSPERO CRD42016034145
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Background
Sexually transmitted infection with high-risk, oncogenic
strains of human papillomavirus (HPV) imposes a sig-
nificant economic burden on public health providers.
Much of the information on HPV centres on women
since having the virus increases the risk of invasive
cervical cancer. But HPV virus may cause other neoplas-
tic benign and malignant lesions, equally affecting men
and women [1]. The total lifetime costs attributable to
non-cervical, HPV-induced diseases were found compar-
able for both sexes [2].
Over the last decade, the advent of the bivalent
(Cervarix, GlaxoSmithKline) and the quadrivalent
(Gardasil, Merck Sharp & Dohme) vaccine in addition to
screening paradigms held promise for reducing the long-
term, cumulative burden of HPV-induced diseases. The
trade-off was an incremental annual investment in
vaccination programmes. Under the constraint of scarce
public resources, policy makers relied on economic valu-
ation to inform the decision to add the HPV vaccination
to existing immunisation programmes. According to
previously published reviews, most cost-effectiveness
studies in the extant literature evaluated women-only
direct immunisation programmes [3–5]. The few studies
which included males in the valuation of HPV vaccin-
ation seemed to reach controversial conclusions [6, 7]. A
recent review focused on a range of values missing from
most studies, such as indirect costs, right to access treat-
ment and health equalities [8].
The unresolved dichotomy between public health
leaders who advocate the urgency of vaccinating boys
against HPV [9] and policy makers who are hesitant
to allocate economic resources to universal (boys and
girls) vaccination calls for a methodological review of
the cost-effectiveness models used to inform the deci-
sions of the latter.
The primary aim of this review is to test the ecological
validity of the cost-effectiveness models available in the
literature. This can be framed by asking if the models
provide an acceptable representation of the intended
reality on all relevant dimensions.
This systematic review protocol will adhere to the report-
ing guidelines of the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses Protocols (PRISMA-P)
statement [10]. The PRISMA-P checklist can be found in
Additional file 1.
Ecological validity
Ecological validity has typically been taken to refer to
whether or not one can generalise from observed behav-
iour in the laboratory to natural behaviours in the world
[11]. In fact, ecological validity or the related idea of
external validity has a long history in psychology and
economics, with the issues central to this idea frequently
and continuously debated [12].
The demand for ecological validity stems from the
Brunswick’s concept of representative design, a construct
used to assess whether an experiment or a model cap-
tures the relevant features of intended realities [13].
Using the replica model analogy [14], this can be framed
by asking how well the model mimics reality on charac-
teristics relevant to the theory. Central to representative
design is the notion that any model can be thought as a
sample of behaviours. For results to be generalisable, not
only should attributes of participants be representative
but also their expected behaviours in the specific task or
situation. To do this, investigators need to specify the
relevant characteristics and behaviour of the population
related to the intended situation. In addition, sampling
should take place on two dimensions. One involves the
participants; the other concerns the situations or tasks
with which the participants are confronted. Valid infer-
ences can only be achieved by sampling in a representa-
tive manner on both dimensions.
Applied to cost-effectiveness of universal HPV vaccin-
ation, models chosen to inform public immunisation
policies should take into account most of the dimensions
relevant to the population (individuals susceptible to
HPV infection) as well as to the specific situation (pat-
terns of sexual mixing).
Challenges of modelling sexual behaviour
Traditionally, patterns of sexual behaviour have been
characterised by focusing on the individual as unit of
analysis, e.g. by measuring an individual’s number of
sexual partners. However, adopting a network approach
to the epidemiology of sexually transmitted infections
reveals that behaviours and sexual preferences may in-
fluence the spread of infection [15]. The ecological the-
ory of infectious disease discusses the characteristics of
the individuals and the patterns of the sexual mixing
relevant to HPV infection [16]. Gender, age, ethnicity,
sexual activity, rate of change of sexual partners and
frequency of unprotected sex are characteristics repre-
sentative of individuals at risk of infection [17–19].
Concurrent partnership and assortative mixing are rele-
vant to the model’s representativeness of sexual mixing.
Concurrent partnerships are those in which the same
individual is involved in sexual partnerships occurring
simultaneously, as opposed to “serial monogamy” where
one partnership ends before another one starts. The pro-
portion of concurrent partnerships effectively increases
the risk of sexually transmitted infections in the popula-
tion [20, 21]. The risk of infection varies according to
whether partnerships are formed between people from
similar (positive assortative) or different (negative as-
sortative) prevalence and sexual activity groups. Sex with
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partners of the same sex (positive) [22], sex with older
partners (negative) [23], sex with a foreign partner
(negative) [24] and pay for sex (negative) [25] are the
four behaviours which increase the heterogeneity in the
population, since some susceptible individuals are more
likely to acquire and transmit the infection. If the high-
risk individuals mix randomly, the infection is more
likely to spread [26].
Building upon the same methodological premise of ecol-
ogy of infectious disease, the Natsal survey is aimed to
understand the most current characteristics of sexual part-
ners and partnerships in the general British population.
Three Natsal surveys have taken place up to day: Natsal-1
in 1990–1991, Natsal-2 in 1999–2001 and Natsal-3 in
2010–2012. In the Natsal-3 [27, 28], the following five
characteristics have been identified to be representative of
the participants (sexually active individuals):
– Number of susceptible individuals (population size
and growth)
– Gender
– Age
– Ethnicity
– Self-defined sexual identity
The following five behaviours have been identified as
representative of situation (sexual mixing):
– Sexual activity (rate of change of sexual partners)
– Concurrent sexual partnerships
– At least one sexual partner from outside the UK
– Paid for sex
– Frequency of unprotected sex
Individual characteristics and sexual mixing behav-
iours are relevant to the ecological validity of modelling
sexually transmitted infections. For the normative out-
comes of cost-effectiveness of universal HPV vaccination
to be generalisable and inform public health policies,
claims need to be established for the representative de-
sign of their underlying models. Ex ante, valid inferences
should only be drawn by models which include all the
eleven dimensions relevant to individuals and their
sexual partner network. Ex post, the relative degree of
representativeness of cost-effectiveness studies can be
assessed by the number of relevant characteristics and
behavioural patterns taken into consideration by their
underlying models.
Study rationale and objectives
The aim of this review is to test the ecological validity of
the cost-effectiveness models of universal HPV vaccin-
ation available in the literature.
Ecological validity refers to the relation between real-
world phenomena and the investigation of these phe-
nomena in experimental contexts or models. This can
be framed by asking if the models provide an acceptable
representation of the intended reality on all relevant
dimensions. In the context of sexually transmitted dis-
eases, patterns of sexual behaviour have been tradition-
ally characterised by focusing on the individual as unit
of analysis, e.g. by measuring an individual’s number of
sexual partners. However, adopting a network approach
to the epidemiology of sexually transmitted infections
reveals that behaviours and sexual preferences may
influence the spread of infection.
For results to be generalisable, not only should
attributes of participants be representative but also their
expected behaviour in the sexual mixing.
The review seeks to answer the following research
questions:
– From the perspective of ecological validity, are the
economic models included in the review
representative of real-life sexual attitudes and
lifestyles?
– To what degree would an ecological bias threaten
the generalisability of the outcomes?
– What are the possible implications on public health
policies?
Methods
Protocol
The protocol is registered in the International Prospective
Register of Systematic Reviews (PROSPERO) CRD420160
34145, available at: http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42016034145
The current stage of the systematic review, as defined
by PROSPERO, is:
2. Piloting of the study selection process.
Eligibility criteria
Inclusion criteria are as follows:
1. Studies reporting the incremental cost-effectiveness
ratio (ICER) per quality-adjusted life year (QALY)
gained of adding males to a female-only HPV
vaccination
2. Health outcomes not limited to cervical cancer and
genital warts but including additional HPV-induced
diseases, such as:
– Vulvar cancer
– Vaginal cancer
– Anal cancer
– Penile cancer
– Oropharyngeal cancer
– Recurrent respiratory papillomatosis (RRP)
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3. Studies will be included if HPV universal vaccination
will be compared to:
– Cervical cancer screening
– Vaccination of females only
4. Studies reporting a full disclosure of the inputs
chosen to inform the economic model
5. Types of economic models:
– Individual models
– Static models
– Transmission dynamic models
– Hybrid models
Exclusion criteria:
1. Health outcomes limited to the valuation of cervical
cancer and genital warts
2. Studies not published in English language
Information sources
The following bibliographic databases will be searched:
MEDLINE (via PubMed); Scopus; Science Direct; EMBASE
(via OVID SP); Web of Science; EconLit (via EBSCO);
DARE, NHIR EED and HTA (via CRD); and CINHAL Plus.
An additional search for grey literature will be conducted
on Google Scholar and Open Grey. Reviews will be in-
cluded to reduce the possibility of missing relevant articles.
Search strategy
A search strategy will be developed for each of the main
databases. Additional file 2 reports details of our
planned bibliographic database search strategies for
MEDLINE (via PubMed); Science Direct; EMBASE (via
OVID SP); Web of Science; Scopus; CRD; CINHAL Plus;
EconLit (via EBSCO); Google Scholar; and Open Grey.
The PubMed “related articles” search feature will be
used to reduce the risk of missing relevant articles.
References of the included studies will be searched in
order to identify additional relevant studies missed. A
pilot of the study selection process will be conducted be-
fore initiating the systematic search of relevant articles.
Study selection
Two graduate research associates (GRAs) will independ-
ently identify through database searching, screen, assess
for eligibility and include in the review the relevant
studies. Opinion of one of the reviewers will be sought
to arrive at a consensus in case of disagreement on a
study for inclusion.
Data extraction
Data will be extracted and recorded independently by
two additional graduate research associates (GRAs) from
the studies included in the review, according to a prede-
fined data extraction table reported in Additional file 3.
Data extracted will be clustered and prioritised: the
main outcomes will report the inputs to the demo-
graphic and epidemiological model, while additional out-
comes will refer to basic inputs to the cost-effectiveness
valuation.
Monetary values in different currencies will be trans-
formed in US dollars using purchasing power parities
(PPPs). Subsequently, all the monetary values will be ad-
justed to 2015 dollar value using the US consumer price
index (CPI). Corresponding authors of various studies
may be contacted by email to clarify methods and results
if the need arises.
Risk of bias
Two external experts (a health economist and a clinical
oncologist) will independently assess the risks and
threats to validity relative to each of the studies in-
cluded in the review. The critical appraisal of included
economic evaluations will be carried out in two subse-
quent stages:
– A preliminary stage, aimed to assess the risk of bias
in the estimates of treatment effect (e.g. vaccine
efficacy) used as data inputs in the economic
evaluation. The effectiveness of the HPV vaccines
currently available has been preliminarily evaluated
by the randomized clinical trials which supported
regulatory approval [29]. Vaccines effect and impact
of immunisation programmes have been confirmed
by post-licensure observational studies [30]. The
choice of the appropriate tool to assess risk of bias
should reflect relevant differences in the study
design. Based on the premise that both randomized
clinical trials and observational studies could be
equally useful to inform the estimates of relative
treatment effect in cost-effectiveness models, the
risk of bias will be assessed by using one of the
following tools:
– The Cochrane Risk of Bias tool [31] for
randomized clinical trials, available online at
http://handbook.cochrane.org/index.htm#chapter
_8/figure_8_6_c_example_of_a_risk_of_bias_
summary_figure.htm
– The Cochrane ROBINS-I tool (Risk Of Bias In
Non-randomized Studies – of Interventions) [32]
for observational studies. The ROBINS-I tool is
available online at: https://sites.google.com/site/
riskofbiastool/welcome/home
– A main stage, aimed to identify additional risks of
bias and, ultimately, to assess the validity of the
included studies. The risk assessment will follow the
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) approach [33]. The CHEERS
statement is available online at: http://www.equator-
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network.org/wp-content/uploads/2013/04/Revised-
CHEERS-Checklist-Oct13.pdf.
In case of misalignment of views, differences will be
resolved in a dedicated meeting among reviewers.
Data synthesis
Each study included in the review will be scored by the
number of representative characteristics and behaviours
taken into consideration (yes or no) on both dimensions.
Individual study’s scores will be plotted in a 2 by 2
matrix [34] reported in Additional file 4.
The upper right quadrant represents the ideal situ-
ation, in which both individuals’ characteristics and
their sexual partner networks are representatives;
hence, the studies are ecologically valid. In the upper
left quadrant, we have models describing representative
individuals but not in a representative network. In the
lower left quadrant, the network is representative but
the individuals are not. Finally, in the lower right quad-
rant, neither the individuals nor the network are repre-
sentative. Only models in the upper right quadrant
provide normative economic recommendations that are
fully representative, hence generalisable to inform pub-
lic health policies.
Discussion
This protocol describes a systematic review of cost-
effectiveness evaluations of universal vaccination pro-
grammes against HPV. The primary aim of this review
is to test the ecological validity of these models, defined
as the degree of representativeness of the individuals
susceptible to infection and their sexual preferences
and lifestyles.
Eventual gaps identified in this systematic review
would have a significant impact on current public
health policies. Models in the extant literature seem to
converge on the cost-effectiveness of high coverage
(>80%) of a single cohort of 12-year-old girls. This vac-
cination strategy should provide an adequate level of
indirect protection (herd immunity) to the unvaccin-
ated boys. This argument presupposes the ecological
validity of the cost-effectiveness models; the implicit
condition that the characteristics of the individuals and
the sexual behaviours observed in the models is gener-
alisable to the natural behaviours of the population. If
the ecological validity condition is violated, an error in
estimating the protective impact of herd immunity
would occur. Hence, a vaccination policy informed on
ecologically invalid models would potentially expose
boys to a residual risk of contracting HPV-induced
malignancies.
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